TRDA

Entrada Therapeutics Inc

4.41

Oct 23 • 3:59 PM ET -0.32 (-6.77%)

4.30

Aftermarket • 7:30 PM ET -0.11 (-2.40%)

Healthcare Biotechnology USA Micro NASD

Peers: DYN PEPG SRPT WVE SLDB CAPR EWTX IONS ARWR PRQR

| Held by: VTI IWM VXF IWN VTWO IBB SCHA IWC DFAS DFMC

Scroll to Statements

Index	RUT
Market Cap	171.73M
Enterprise Value	-2.73M
Income	-165.78M
Sales	4.69M
Book/sh	5.99
Cash/sh	5.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	152
IPO	Oct 29, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	36.62
P/B	0.74
P/C	0.77
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.58
Quick Ratio	10.89
Current Ratio	10.89
Debt/Eq	0.21
LT Debt/Eq	0.19
Option/Short	Yes / Yes

EPS (ttm)	-3.97
EPS next Y	-3.37
EPS next Q	-1.01
EPS this Y	-11.89%
EPS next Y	13.20%
EPS next 5Y	4.82%
EPS past 3/5Y	-4.74% -32.56%
Sales past 3/5Y	- -
EPS Y/Y TTM	-122.58%
Sales Y/Y TTM	-94.10%
EPS Q/Q	2.87%
Sales Q/Q	-53.95%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	3.75% -59.81%

Insider Own	38.60%
Insider Trans	-8.96%
Inst Own	53.40%
Inst Trans	1.57%
ROA	-44.35%
ROE	-54.09%
ROIC	-59.74%
Gross Margin	21.23%
Oper. Margin	-3767.07%
Profit Margin	-3537.73%
SMA20	-16.21%
SMA50	-30.39%
SMA200	-50.52%
Trades

Shs Outstand	38.94M
Shs Float	23.91M
Short Float	12.50%
Short Ratio	8.36
Short Interest	2.99M
52W High	16.45 -73.19%
52W Low	4.11 7.32%
Volatility	8.97% 8.92%
ATR (14)	0.44
RSI (14)	33.58
Beta	-0.22
Rel Volume	0.54
Avg Volume	357.44K
Volume	191,473

Perf Week	0.92%
Perf Month	-29.10%
Perf Quarter	-27.47%
Perf Half Y	-65.08%
Perf YTD	-57.10%
Perf Year	-31.09%
Perf 3Y	-70.91%
Perf 5Y	-
Perf 10Y	-
Recom	1.29
Target Price	17.00
Prev Close	4.73
Price	4.41
Change %	-6.77%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-26	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-01-26	Initiated	Cantor Fitzgerald	Overweight
Feb-11-26	Initiated	Guggenheim	Buy	$20
Jan-28-26	Initiated	Oppenheimer	Outperform	$21
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Oct-21-26 07:00AM	Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer (GlobeNewswire) -6.81%
Oct-14-26 07:00AM	Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study (GlobeNewswire) -6.38%
07:00AM	Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 (GlobeNewswire)
Sep-10-26 07:00AM	Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program (GlobeNewswire) -9.70%
Sep-02-26 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Aug-05-26 07:00AM	Entrada Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jun-02-26 07:00AM	Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study (GlobeNewswire)
Jun-01-26 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-26 06:39AM	Entradas stock drops as DMD drugs efficacy falls short (Clinical Trials Arena)
May-07-26 07:14AM	Entrada shares dive as Duchenne results disappoint (BioPharma Dive) -57.27%
07:10AM	Entrada Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire)
07:00AM	Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study (GlobeNewswire)
May-06-26 04:30PM	Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 (GlobeNewswire)
Mar-02-26 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +6.76%
07:25PM	Loading…
Feb-25-26 07:25PM	Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-24-26 09:40AM	Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-19-26 10:00AM	Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline (Zacks)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
Feb-17-26 07:00AM	Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study (GlobeNewswire)
Feb-15-26 03:02PM	Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit (MarketBeat)
Feb-05-26 06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks) -6.93% +5.26%
Feb-04-26 07:40AM	Techne (TECH) Beats Q2 Earnings and Revenue Estimates (Zacks) -8.23%
07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-26 07:16AM	Entrada Therapeutics reports progress across development portfolio (TipRanks)
Jan-08-26 07:00AM	Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases (GlobeNewswire)
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 07:00AM	Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 08:30AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Entrada Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 08:10AM	Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-29-25 07:46AM	Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? (Zacks) -6.26%
Oct-28-25 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-05-25 07:00AM	Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program (GlobeNewswire)
Sep-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 10:15AM	Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -11.45%
Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
Jun-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.11%
May-29-25 11:10AM	Entradas Phase I/II trial of DMD treatment authorised to begin in EU (Clinical Trials Arena)
May-28-25 07:00AM	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MPM BIOVENTURES 2018, L.P.	10% Owner	Sep 08 '26	Sale	7.41	192,500	1,426,425	3,913,952	Sep 09 07:24 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Sep 04 '26	Sale	7.11	38,500	273,735	4,106,452	Sep 09 07:24 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Sep 09 '26	Sale	7.13	28,837	205,608	3,885,115	Sep 09 07:24 PM
MPM BioVentures 2014, L.P.	10% Owner	Sep 08 '26	Sale	7.41	192,500	1,426,425	3,913,952	Sep 09 07:23 PM
MPM BioVentures 2014, L.P.	10% Owner	Sep 04 '26	Sale	7.11	38,500	273,735	4,106,452	Sep 09 07:23 PM
MPM BioVentures 2014, L.P.	10% Owner	Sep 09 '26	Sale	7.13	28,837	205,608	3,885,115	Sep 09 07:23 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Sep 03 '26	Sale	7.17	32,263	231,326	4,144,952	Sep 03 07:21 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Sep 01 '26	Sale	7.06	29,088	205,361	4,202,346	Sep 03 07:21 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Sep 02 '26	Sale	7.19	25,131	180,692	4,177,215	Sep 03 07:21 PM
MPM BioVentures 2014, L.P.	10% Owner	Sep 03 '26	Sale	7.17	32,263	231,326	4,144,952	Sep 03 07:21 PM
MPM BioVentures 2014, L.P.	10% Owner	Sep 01 '26	Sale	7.06	29,088	205,361	4,202,346	Sep 03 07:21 PM
MPM BioVentures 2014, L.P.	10% Owner	Sep 02 '26	Sale	7.19	25,131	180,692	4,177,215	Sep 03 07:21 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Aug 31 '26	Sale	6.99	44,259	309,370	4,231,434	Aug 31 06:26 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Aug 27 '26	Sale	7.20	38,922	280,238	4,279,426	Aug 31 06:26 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Aug 28 '26	Sale	7.01	3,733	26,168	4,275,693	Aug 31 06:26 PM
MPM BioVentures 2014, L.P.	10% Owner	Aug 31 '26	Sale	6.99	44,259	309,370	4,231,434	Aug 31 06:25 PM
MPM BioVentures 2014, L.P.	10% Owner	Aug 27 '26	Sale	7.20	38,922	280,238	4,279,426	Aug 31 06:25 PM
MPM BioVentures 2014, L.P.	10% Owner	Aug 28 '26	Sale	7.01	3,733	26,168	4,275,693	Aug 31 06:25 PM
MPM BioVentures 2014, L.P.	10% Owner	Aug 25 '26	Sale	7.54	26,522	199,976	4,332,917	Aug 26 09:28 PM
MPM BioVentures 2014, L.P.	10% Owner	Aug 24 '26	Sale	7.34	21,623	158,713	4,359,439	Aug 26 09:28 PM
MPM BioVentures 2014, L.P.	10% Owner	Aug 26 '26	Sale	7.06	14,569	102,857	4,318,348	Aug 26 09:28 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Aug 25 '26	Sale	7.54	26,522	199,976	4,332,917	Aug 26 09:27 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Aug 24 '26	Sale	7.34	21,623	158,713	4,359,439	Aug 26 09:27 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Aug 26 '26	Sale	7.06	14,569	102,857	4,318,348	Aug 26 09:27 PM
PARMAR KUSH	Director	Aug 10 '26	Sale	7.00	92,444	647,108	2,691,337	Aug 10 07:54 PM
PARMAR KUSH	Director	Aug 07 '26	Sale	6.85	52,317	358,371	2,783,781	Aug 10 07:54 PM
PARMAR KUSH	Director	Aug 06 '26	Sale	7.00	10,494	73,458	2,836,098	Aug 10 07:54 PM
5AM Ventures V, L.P.	10% Owner	Aug 07 '26	Sale	6.85	52,317	358,371	2,783,781	Aug 10 07:52 PM
5AM Ventures V, L.P.	10% Owner	Aug 06 '26	Sale	7.00	10,494	73,458	2,836,098	Aug 10 07:52 PM
5AM Ventures V, L.P.	10% Owner	Jul 30 '26	Sale	6.93	114,756	795,259	2,848,310	Aug 03 05:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 31 '26	Sale	6.85	1,718	11,768	2,846,592	Aug 03 05:32 PM
PARMAR KUSH	Director	Jul 30 '26	Sale	6.93	114,756	795,259	2,848,310	Aug 03 05:26 PM
PARMAR KUSH	Director	Jul 31 '26	Sale	6.85	1,718	11,768	2,846,592	Aug 03 05:26 PM
5AM Ventures V, L.P.	Affiliated stockholder	Jul 30 '26	Proposed Sale	6.55	331,156	2,169,072		Jul 30 05:39 PM
Zeiher Bernhardt G	Director	May 20 '26	Buy	5.86	5,000	29,316	5,000	May 21 04:31 PM
Sethuraman Natarajan	President, Research & Develop.	May 04 '26	Sale	15.39	25,907	398,810	216,317	May 04 07:25 PM
Dowden Nathan J	President & COO	May 04 '26	Option Exercise	1.74	15,000	26,100	213,588	May 04 07:24 PM
Dowden Nathan J	President & COO	May 04 '26	Sale	15.33	15,000	229,953	198,588	May 04 07:24 PM
NATHAN DOWDEN	Officer	May 04 '26	Proposed Sale	14.50	15,000	217,500		May 04 04:33 PM
NATARAJAN SETHURAMAN	Officer	May 04 '26	Proposed Sale	14.50	25,907	375,652		May 04 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 01 '26	Sale	12.95	2,500	32,375	119,010	Apr 02 04:39 PM
KORY WENTWORTH	Officer	Apr 01 '26	Proposed Sale	12.62	2,500	31,550		Apr 01 04:38 PM
Dowden Nathan J	President & COO	Mar 10 '26	Sale	13.05	11,894	155,188	198,588	Mar 11 04:35 PM
Dowden Nathan J	President & COO	Mar 09 '26	Sale	13.02	3,116	40,583	210,482	Mar 11 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 10 '26	Sale	13.02	11,388	148,216	121,510	Mar 11 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 09 '26	Sale	13.00	5,089	66,163	132,898	Mar 11 04:34 PM
KORY WENTWORTH	Officer	Mar 09 '26	Proposed Sale	12.58	16,477	207,281		Mar 09 04:37 PM
NATHAN DOWDEN	Officer	Mar 09 '26	Proposed Sale	12.58	15,010	188,826		Mar 09 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 04 '26	Sale	12.25	7,988	97,892	137,987	Mar 06 04:36 PM
KORY WENTWORTH	Officer	Mar 04 '26	Proposed Sale	11.85	7,988	94,658		Mar 04 05:11 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 21 '25	Sale	9.98	8,910	88,932	110,026	Nov 24 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 20 '25	Buy	9.07	28,867	261,846	4,691,392	Nov 24 04:09 PM
KORY WENTWORTH	Officer	Nov 21 '25	Proposed Sale	9.17	8,910	81,705		Nov 21 04:45 PM
PARMAR KUSH	Director	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:36 PM
5AM Ventures V, L.P.	10% Owner	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:34 PM
5AM Ventures V, L.P.	Affiliated Stockholder	Nov 14 '25	Proposed Sale	8.80	200,000	1,760,664		Nov 14 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 12 '25	Buy	7.76	100,736	781,638	4,664,924	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 11 '25	Buy	7.50	46,434	348,193	4,572,549	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 10 '25	Buy	7.21	30,874	222,756	4,529,969	Nov 12 05:34 PM

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which provides of a class of medicines that engages in intracellular targets. Its Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The company was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

CEO & DirectorMr. Dipal Doshi

President & COOMr. Nathan J. Dowden

President of Research & DevelopmentDr. Natarajan Sethuraman Ph.D.

CFO & TreasurerMr. Kory James Wentworth CPA

Ph.D.Dr. Jared Cohen J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRDA

Entrada Therapeutics Inc

Upgrade your Finviz experience